Cerus Corp (CERS) beats Q2 2026 revenue by 7.5% on INTERCEPT surge
As seen on the 24/7 Wall St. homepage on July 30, 2026.
Cerus beat revenue expectations by 7.5% as its INTERCEPT blood safety franchise surges, with the company now guiding for 40% to 50% growth in fibrinogen product sales through year-end.
Continue ReadingShow less
Cerus reported Q2 2026 revenue of $63.3 million, topping analyst estimates of roughly $58.9 million by about 7.5%. That result continues a steady upward trend in quarterly sales that stretches back to Q1 2025, with revenue climbing from $43.2 million that quarter to more than $63 million now. The company's earnings per share came in at -$0.01, exactly in line with the consensus estimate.
The growth engine behind the beat is the INTERCEPT blood safety franchise, which the company cited as surging heading into the second half of the year. Particularly notable is management's forward guidance on fibrinogen product sales, where Cerus is now projecting 40% to 50% growth through year-end — a range that signals confidence in accelerating commercial momentum for that specific product line.
Investors will want to track whether the fibrinogen growth guidance materializes in coming quarters, and whether the broader INTERCEPT franchise can sustain the revenue trajectory that has lifted quarterly sales from roughly $45 million in Q2 2024 to more than $63 million today.
Mentioned: CERS
Disclosure
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.